Hongtai Capital

Hongtai Fund was co-founded in 2014 by entrepreneur Mr. Yu Minhong and senior investment banker Mr. Sheng Xitai, primarily investing in five major fields: information technology, advanced manufacturing, pharmaceuticals and healthcare, new consumption, and new materials. Investment and compliance risk control are the two core strengths of Hongtai Fund. To date, Hongtai Fund manages assets exceeding 30 billion RMB. In early-stage projects, Hongtai Fund has invested in companies such as Thunisoft (Shenzhilan), Yidianyun (Easypoint), Xiaoxiandun (Xiaoxian Dun), Werewolf Kill, Deepwise Healthcare (Shenrui Medical), Nreal (Tairuo Technology), Dingjia Hongsi (Dingjia Hongsi), Pensight Technology (Pengsi Technology), DaV Shop (DaVdian), Xiaoku Technology, Shumi Technology, Shulan Technology, Ruida Aerospace, AIFI, Tanjing Technology, Xiangxin Technology (FaceUnity), Sunac Microelectronics (Rongchuang Microelectronics), Yunsheng Intelligent (Yunsheng Zhineng), Xinge Intelligent (Xinge Zhineng), Zhongke Precision Engineering (Zhongke Jinggong), Haizhi Online (Haizhi Zaixian), Lanyang Technology, Mingjia Semiconductor, Chuanxin Biotech (Chuanxin Shengwu), Aikenuo Biotech (Aikenuo Shengwu), Yinuo Pharmaceutical (Yinnuo Pharmaceutical) and other projects, leading in their respective segments*. In mid-to-late-stage projects, Hongtai Fund has invested in companies such as KK Group, Linuo Glass (Linuo Teboli), Hanyi Fonts (Hanyi Ziku), Haichuang Pharmaceutical (Haichuang Yaoye), Jiuxian.com (Jiuxianwang), Feishu Shennuo (Feishu Shennuo), Orbbec (Aobizhongguang), Ketuo Parking, Yuanren Innovation (Yuanren Chuangxin), Nenglian Group (Nenglian Group), Changli New Materials (Changli Xincai), SPIC Hydrogen Energy (Guodian Touqing Neng), Qingdao Qinghe (Qingdao Qinghe), COSMOPlat (Ka'ao Si), Shuju Zhilian (Shuju Zhilian), Guoxing Aerospace (Guoxing Hangtian), Xinyun Group (Xingyun Group), Moore Threads (Moore Xiancheng), Yushi Technology (Yushi Keji), Anyu Biotech (Anyu Shengwu), Huakan Biotech (Huakan Shengwu), Shengshi Taike, Quanxin Biotech (Quanxin Shengwu), Huanlong New Materials (Huanlong Xincai)/Babu, Gusen Pharmaceutical (Gusen Yiyao), Weidian Biotech (Weidian Shengwu), Meishubao, Zhongmo Cloud (Zhongmo Yun), ActionPower (Aikesaibo), Grainger (Gu'anjie), Zhaoyan Biotech (Zhaoyan Shengwu), Dongdong Technology and a group of other high-quality enterprises. With a rigorous investment research system, focused investment layout, and an experienced investment team, Hongtai Fund has developed rapidly with outstanding performance, gaining high recognition from all parties and being selected as a Class A private equity fund manager by the China Insurance Asset Management Association (CIAMA). Hongtai Fund possesses systematic strategies and a strong team. Its unique combination of founders and comprehensive team background enables Hongtai Fund to be deeply familiar with every stage from startup to IPO for entrepreneurs, wielding broad and profound influence among Chinese entrepreneurs and listed companies. Adhering to the values of "Upholding Integrity · Driving Innovation, Empowering Others · Achieving Shared Success," Hongtai Fund is committed to becoming an outstanding industry integrator and innovation promoter, serving industry, contributing to society, and specializing in national advancement.